depigmented polymerized phleum pratense pollen extract

Depigmented polymerized Phleum pratense pollen extract (marketed under the brand name Depigoid Phleum) is an allergen immunotherapy product (allergoid) developed by Laboratorios LETI. The active ingredient is a chemically modified extract of *Phleum pratense* (timothy grass) pollen that has been depigmented to remove low-molecular-weight, non-allergenic components and subsequently polymerized using glutaraldehyde. This modification reduces the extract's IgE-binding capacity (allergenicity) while preserving its T-cell reactivity (immunogenicity), thereby minimizing the risk of IgE-mediated systemic allergic reactions (anaphylaxis) and allowing for rapid up-dosing. The immunotherapy works by inducing immune tolerance, promoting the generation of allergen-specific IgG4 and IgA antibodies, and stimulating regulatory T (Treg) and regulatory B (Breg) cells that secrete anti-inflammatory cytokines like IL-10. It is developed for the treatment of grass pollen-induced allergic rhinoconjunctivitis and asthma, and has been evaluated in clinical trials for both subcutaneous (SCIT) and sublingual (SLIT) administration.

Brand names

Depigoid PhleumDepigoid Phleum pratense

Other names

depigmented-polymerized Phleum pratense pollen extractdepigmented glutaraldehyde-polymerized Phleum pratense pollen extractDPG-POL-Phl p